Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.3.1 (alkaline phosphatase)
 47,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A study was carried out in 40 patients with primary hyperlipoproteinaemia to compare the efficacy and tolerance of bezafibrate and fenofibrate, combined with a dietary regimen, in reducing lipid levels. Patients were allocated at random to receive treatment for 4 months with either 600 mg bezafibrate or 300 mg fenofibrate per day. Efficacy of treatment was assessed from measurement before and after treatment of the levels of total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides and blood glucose. Tolerance was monitored by monthly clinical examinations and routine investigation of blood chemistry and urinalysis before and after treatment. The results indicated that bezafibrate was a more effective normolipaemic agent than fenofibrate. Whilst both drugs reduced triglyceride levels significantly, only in the bezafibrate group were they decreased to within the risk-free range. Bezafibrate also produced a significant decrease in total cholesterol and LDL-cholesterol to near the risk-free level and an increase in HDL-cholesterol. With fenofibrate, total cholesterol and LDL-cholesterol levels remained within the range necessitating treatment and HDL-cholesterol showed little if any change. Although there were decreases in alkaline phosphatase and significant decreases in gamma-glutamyl transpeptidase levels in both groups after treatment, there was a tendency for SGPT, SGOT, total bilirubin and direct bilirubin levels to increase after fenofibrate but to decrease after bezafibrate.
 ...
PMID:Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoproteinaemia. 390 79

Chronic GVHD (cGVHD) of the liver is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-SCT). It is characterized by the destruction of bile duct epithelium followed by progressive cholestasis, which resembles primary biliary cirrhosis (PBC) clinically and histologically. Bezafibrate (BF) is a widely used agent for hyperlipidemia that is also effective in ursodeoxycholic acid (UDCA)-resistant PBC patients. The putative mechanism in cholestasis is that BF upregulates the expression of phosphatidylcholine flippase on bile canaliculi, facilitates phospholipid output into bile and relieves bile duct damage caused by hydrophobic bile salts. Therefore, the effects of BF in patients with cGVHD of the liver were investigated. Of 87 patients with cGVHD who survived more than 100 days after SCT, 8 were given BF to treat liver cGVHD because of a poor therapeutic response to UDCA and immunosuppressants. The serum alkaline phosphatase (ALP) and gamma-glutamyl transpeptidase (gamma-GTP) levels decreased significantly within 1 month after initiation of BF therapy compared with those before BF therapy in all patients (ALP, 964.9.0+/-306.9 to 597.8+/-102.5 IU/l, P=0.012; gamma-GTP, 528.8+/-299.0 to 269.0+/-119.9 IU/l, P=0.012). BF was effective in patients with liver cGVHD, including UDCA-resistant patients. BF could be a novel therapeutic option for liver cGVHD that helps to preserve normal immunity with the antileukemic effect of cGVHD.
 ...
PMID:Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. 1980 24